CoChat

Psychiatric Adverse Events Associated with Varenicline: An Intensive Postmarketing Prospective Cohort Study in New Zealand

Harrison-Woolrych, Mira, Ashton, Janelle · 2011 · Drug Safety

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

Background Psychiatric adverse events, including depression, suicidal ideation and psychotic reactions have been reported in patients taking the smoking cessation medicine varenicline. However, data regarding the frequency of psychiatric adverse reactions in 'real-life' postmarketing use are limited to date.Objective The aim of the study was to calculate the occurrence rates of psychiatric adverse reactions in a nationwide general population prescribed varenicline in New Zealand.Methods Observational prospective cohort study using Prescription Event Monitoring methods. All New Zealand patients dispensed a prescription for varenicline from 1 April 2007 to 31 March 2008 were included in this study. Patients were followed up by multiple methods, including linkage to national morbidity and mortality datasets, questionnaires to patients' doctors and assessment of spontaneous reports sent to the Intensive Medicines Monitoring Programme. Main outcome measures were occurrence rates of psychiatric adverse events in the total patient cohort and in the subgroup for whom a follow-up questionnaire was returned (the 'responder population').Results The cohort for this study included 3415 patients prescribed varenicline during the first year of monitoring in New Zealand. Follow-up by record linkage was performed for 3353 (98%) patients, and questionnaires were returned for 1394 (42%) of these patients. Of 1394 questionnaires returned, 1310 were valid and defined as the 'responder' population. Sleep disorders, including insomnia, sleep disturbance, dreams and nightmares, were the most frequently reported psychiatric events and were experienced by 56 (4.3%) patients in the responder population. Symptoms of depression were reported by 39 (2.98%) patients in the responder population (24 new-onset depression, 14 worsening of pre-existing depression and 1 report of impaired motivation). Withdrawal reactions after stopping varenicline were reported by 6 (0.46%) patients in the responder population. Serious psychiatric reactions including suicide (one case), suicidal ideation (two cases) and psychotic reactions (three cases) were also identified. Six self-harm events (one fatal, five non-fatal) were identified in the total cohort, giving an occurrence rate of 0.18% (95% CI 0.06, 0.38) in this population.Conclusions This intensive postmarketing study of 3415 New Zealand patients demonstrates that psychiatric adverse events are commonly reported in patients taking varenicline. Approximately 3% of patients experienced symptoms of depression and the majority of these cases appeared to have a causal association with varenicline. Serious psychiatric reactions including suicide, suicidal ideation and psychotic reactions were also identified, but these were less frequently reported.

Overview

Integrity signals

Registry

Crossref · 10.2165/11594450-000000000-00000

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 17 references

Research works printed but not linked: 4

  1. Elijah, 2010 Aug, Aust Prescrib, 33, 120
  2. Kunac, 2008 Oct 3, N Z Med J, 121, 76
  3. Karch, 1975 Dec 22, JAMA, 234, 1236, 10.1001/jama.234.12.1236 · doi:10.1001/jama.234.12.1236 · Paper page
  4. 2009, FDA Drug Saf Newsletter, 2, 1

Cited by

See all 54

Metadata

Authors
Harrison-Woolrych, M., & Ashton, J.
Affiliations
University of Otago (NZ)
Venue
Drug Safety
Published
2011-09
Volume
34
Issue
9
Pages
763-772
ISSN
0114-5916 (ISSN-L)
OpenAlex
W14210466
Cited by
54
References
17
Citations by year
2026: 1 · 2024: 1 · 2023: 2 · 2021: 1 · 2020: 4 · 2019: 3 · 2018: 3 · 2017: 4 · 2016: 5 · 2015: 6 · 2014: 6 · 2013: 8 · 2012: 7
FWCI
9.40
Type
journal article
Language
en
Open access
closed
Locations
  • Drug Safety (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
  • Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
Keywords
varenicline, psychiatric adverse events, depression, suicidal ideation, psychosis, self-harm, insomnia, sleep disorders, withdrawal reactions, smoking cessation, post-marketing surveillance, prescription-event monitoring, New Zealand patients, occurrence rate, data linkage, suicide
MeSH terms
Varenicline, Adult, Aged, Aged, 80 and over, Mental Disorders, Benzazepines, Female, Follow-Up Studies, Humans, Male, Middle Aged, New Zealand, Product Surveillance, Postmarketing, Prospective Studies, Surveys and Questionnaires, Quinoxalines, Sleep Wake Disorders, Cohort Studies, Smoking Cessation, Nicotinic Agonists, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Psychiatric Adverse Events Associated with Varenicline: An Intensive Postmarketing Prospective Cohort Study in New Zealand. https://app.cochat.ai/papers/10.2165/11594450-000000000-00000
The paper
Harrison-Woolrych, M., & Ashton, J. (2011). Psychiatric Adverse Events Associated with Varenicline: An Intensive Postmarketing Prospective Cohort Study in New Zealand. Drug Safety. https://doi.org/10.2165/11594450-000000000-00000

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.